- Home
- AVTX vs ABEO Comparison
AVTX vs ABEO Comparison
Compare AVTX & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | ABEO |
|---|---|---|
| Founded | 2011 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.9M | 280.2M |
| IPO Year | 2015 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AVTX | ABEO |
|---|---|---|
| Price | $17.10 | $5.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $32.57 | $18.75 |
| AVG Volume (30 Days) | 510.9K | ★ 948.5K |
| Earning Date | 04-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.66 | 38.74 |
| EPS | N/A | ★ 1.35 |
| Revenue | ★ $27,813,137.00 | $2,998,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,589.77 |
| P/E Ratio | ★ N/A | $3.80 |
| Revenue Growth | ★ 2312.27 | 258.18 |
| 52 Week Low | $3.39 | $3.93 |
| 52 Week High | $20.72 | $7.54 |
Technical Indicators
Market Signals| Indicator | AVTX | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 54.28 | 46.54 |
| Support Level | $15.36 | $4.87 |
| Resistance Level | $19.26 | $5.60 |
| Average True Range (ATR) | 1.36 | 0.20 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 65.50 | 31.86 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.